Die moderne medikamentöse Behandlung des Parkinsonismus
Identifieur interne : 000638 ( Main/Corpus ); précédent : 000637; suivant : 000639Die moderne medikamentöse Behandlung des Parkinsonismus
Auteurs : W. Birkmayer ; E. NeumayerSource :
- Zeitschrift für Neurologie [ 0012-1037 ] ; 1972-12-01.
Abstract
Summary: Evolution, procedure, results and side effects of modern anti-Parkinson treatment are reported. A notable decrease of dopamin, serotonin and norepinephrin in the brainstem of Parkinson patients suggested a substitution of the precursors of these biogenic amines. The administration of L-DCPA effected an improvement in the akinesia for a short time only. A combination of l-DOPA with a decarboxylase inhibitor (Ro4-4602) produced a more intensive effect over a longer period. Similar results were achieved by high oral dosages, accompanied, however, by marked side effects. The autonomic motor and psychogenic side effects are reported. The DOPA-psychoses are caused by the depletion of serotonin after l-DOPA administration. Raised levels of 5-Hydroxyacetic acid were observed in the C.S.F. of psychotic patients. After administration of l-tryptophan the high values of 5 HIAA fell and the patients showed normal behaviour.
Url:
DOI: 10.1007/BF00316175
Links to Exploration step
ISTEX:37A8F6AFC2350556B8DAF89DB21211B9C932C3FFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="de">Die moderne medikamentöse Behandlung des Parkinsonismus</title><author><name sortKey="Birkmayer, W" sort="Birkmayer, W" uniqKey="Birkmayer W" first="W." last="Birkmayer">W. Birkmayer</name><affiliation><mods:affiliation>L. Boltzmann-Institut für Neurochemie und Neurologische Abteilung der Stadt Wien-Lainz, Österreich</mods:affiliation></affiliation></author><author><name sortKey="Neumayer, E" sort="Neumayer, E" uniqKey="Neumayer E" first="E." last="Neumayer">E. Neumayer</name><affiliation><mods:affiliation>L. Boltzmann-Institut für Neurochemie und Neurologische Abteilung der Stadt Wien-Lainz, Österreich</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:37A8F6AFC2350556B8DAF89DB21211B9C932C3FF</idno><date when="1972" year="1972">1972</date><idno type="doi">10.1007/BF00316175</idno><idno type="url">https://api.istex.fr/document/37A8F6AFC2350556B8DAF89DB21211B9C932C3FF/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000638</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="de">Die moderne medikamentöse Behandlung des Parkinsonismus</title><author><name sortKey="Birkmayer, W" sort="Birkmayer, W" uniqKey="Birkmayer W" first="W." last="Birkmayer">W. Birkmayer</name><affiliation><mods:affiliation>L. Boltzmann-Institut für Neurochemie und Neurologische Abteilung der Stadt Wien-Lainz, Österreich</mods:affiliation></affiliation></author><author><name sortKey="Neumayer, E" sort="Neumayer, E" uniqKey="Neumayer E" first="E." last="Neumayer">E. Neumayer</name><affiliation><mods:affiliation>L. Boltzmann-Institut für Neurochemie und Neurologische Abteilung der Stadt Wien-Lainz, Österreich</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Zeitschrift für Neurologie</title><title level="j" type="abbrev">Z. Neurol.</title><idno type="ISSN">0012-1037</idno><idno type="eISSN">1432-1459</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="1972-12-01">1972-12-01</date><biblScope unit="volume">202</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="257">257</biblScope><biblScope unit="page" to="280">280</biblScope></imprint><idno type="ISSN">0012-1037</idno></series><idno type="istex">37A8F6AFC2350556B8DAF89DB21211B9C932C3FF</idno><idno type="DOI">10.1007/BF00316175</idno><idno type="ArticleID">Art1</idno><idno type="ArticleID">BF00316175</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0012-1037</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="de">de</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: Evolution, procedure, results and side effects of modern anti-Parkinson treatment are reported. A notable decrease of dopamin, serotonin and norepinephrin in the brainstem of Parkinson patients suggested a substitution of the precursors of these biogenic amines. The administration of L-DCPA effected an improvement in the akinesia for a short time only. A combination of l-DOPA with a decarboxylase inhibitor (Ro4-4602) produced a more intensive effect over a longer period. Similar results were achieved by high oral dosages, accompanied, however, by marked side effects. The autonomic motor and psychogenic side effects are reported. The DOPA-psychoses are caused by the depletion of serotonin after l-DOPA administration. Raised levels of 5-Hydroxyacetic acid were observed in the C.S.F. of psychotic patients. After administration of l-tryptophan the high values of 5 HIAA fell and the patients showed normal behaviour.</div></front></TEI><istex><corpusName>springer</corpusName><author><json:item><name>W. Birkmayer</name><affiliations><json:string>L. Boltzmann-Institut für Neurochemie und Neurologische Abteilung der Stadt Wien-Lainz, Österreich</json:string></affiliations></json:item><json:item><name>E. Neumayer</name><affiliations><json:string>L. Boltzmann-Institut für Neurochemie und Neurologische Abteilung der Stadt Wien-Lainz, Österreich</json:string></affiliations></json:item></author><articleId><json:string>Art1</json:string><json:string>BF00316175</json:string></articleId><language><json:string>deu</json:string></language><abstract>Summary: Evolution, procedure, results and side effects of modern anti-Parkinson treatment are reported. A notable decrease of dopamin, serotonin and norepinephrin in the brainstem of Parkinson patients suggested a substitution of the precursors of these biogenic amines. The administration of L-DCPA effected an improvement in the akinesia for a short time only. A combination of l-DOPA with a decarboxylase inhibitor (Ro4-4602) produced a more intensive effect over a longer period. Similar results were achieved by high oral dosages, accompanied, however, by marked side effects. The autonomic motor and psychogenic side effects are reported. The DOPA-psychoses are caused by the depletion of serotonin after l-DOPA administration. Raised levels of 5-Hydroxyacetic acid were observed in the C.S.F. of psychotic patients. After administration of l-tryptophan the high values of 5 HIAA fell and the patients showed normal behaviour.</abstract><qualityIndicators><score>6.62</score><pdfVersion>1.3</pdfVersion><pdfPageSize>447 x 666 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>933</abstractCharCount><pdfWordCount>8391</pdfWordCount><pdfCharCount>54883</pdfCharCount><pdfPageCount>24</pdfPageCount><abstractWordCount>135</abstractWordCount></qualityIndicators><title>Die moderne medikamentöse Behandlung des Parkinsonismus</title><genre><json:string>research-article</json:string></genre><host><volume>202</volume><pages><last>280</last><first>257</first></pages><issn><json:string>0012-1037</json:string></issn><issue>4</issue><subject><json:item><value>Neurosciences</value></json:item><json:item><value>Neuroradiology</value></json:item><json:item><value>Neurology</value></json:item></subject><journalId><json:string>415</json:string></journalId><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1432-1459</json:string></eissn><title>Zeitschrift für Neurologie</title><publicationDate>1972</publicationDate><copyrightDate>1972</copyrightDate></host><publicationDate>1972</publicationDate><copyrightDate>1972</copyrightDate><doi><json:string>10.1007/BF00316175</json:string></doi><id>37A8F6AFC2350556B8DAF89DB21211B9C932C3FF</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/37A8F6AFC2350556B8DAF89DB21211B9C932C3FF/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/37A8F6AFC2350556B8DAF89DB21211B9C932C3FF/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/37A8F6AFC2350556B8DAF89DB21211B9C932C3FF/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="de">Die moderne medikamentöse Behandlung des Parkinsonismus</title><title level="a" type="alt" xml:lang="en">The modern treatment of parkinsonism</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><availability><p>SPRINGER</p></availability><date>1972-07-24</date></publicationStmt><notesStmt><note>Surveys Of Progress</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="de">Die moderne medikamentöse Behandlung des Parkinsonismus</title><title level="a" type="alt" xml:lang="en">The modern treatment of parkinsonism</title><author><persName><forename type="first">W.</forename><surname>Birkmayer</surname></persName><affiliation>L. Boltzmann-Institut für Neurochemie und Neurologische Abteilung der Stadt Wien-Lainz, Österreich</affiliation></author><author><persName><forename type="first">E.</forename><surname>Neumayer</surname></persName><affiliation>L. Boltzmann-Institut für Neurochemie und Neurologische Abteilung der Stadt Wien-Lainz, Österreich</affiliation></author></analytic><monogr><title level="j">Zeitschrift für Neurologie</title><title level="j" type="abbrev">Z. Neurol.</title><idno type="JournalID">415</idno><idno type="pISSN">0012-1037</idno><idno type="eISSN">1432-1459</idno><idno type="IssueArticleCount">8</idno><idno type="VolumeIssueCount">4</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="1972-12-01"></date><biblScope unit="volume">202</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="257">257</biblScope><biblScope unit="page" to="280">280</biblScope></imprint></monogr><idno type="istex">37A8F6AFC2350556B8DAF89DB21211B9C932C3FF</idno><idno type="DOI">10.1007/BF00316175</idno><idno type="ArticleID">Art1</idno><idno type="ArticleID">BF00316175</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1972-07-24</date></creation><langUsage><language ident="de">de</language></langUsage><abstract xml:lang="en"><p>Summary: Evolution, procedure, results and side effects of modern anti-Parkinson treatment are reported. A notable decrease of dopamin, serotonin and norepinephrin in the brainstem of Parkinson patients suggested a substitution of the precursors of these biogenic amines. The administration of L-DCPA effected an improvement in the akinesia for a short time only. A combination of l-DOPA with a decarboxylase inhibitor (Ro4-4602) produced a more intensive effect over a longer period. Similar results were achieved by high oral dosages, accompanied, however, by marked side effects. The autonomic motor and psychogenic side effects are reported. The DOPA-psychoses are caused by the depletion of serotonin after l-DOPA administration. Raised levels of 5-Hydroxyacetic acid were observed in the C.S.F. of psychotic patients. After administration of l-tryptophan the high values of 5 HIAA fell and the patients showed normal behaviour.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>Medicine & Public Health</head><item><term>Neurosciences</term></item><item><term>Neuroradiology</term></item><item><term>Neurology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1972-07-24">Created</change><change when="1972-12-01">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-1">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/37A8F6AFC2350556B8DAF89DB21211B9C932C3FF/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Springer, Publisher found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName><PublisherLocation>Berlin/Heidelberg</PublisherLocation></PublisherInfo><Journal><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>415</JournalID><JournalPrintISSN>0012-1037</JournalPrintISSN><JournalElectronicISSN>1432-1459</JournalElectronicISSN><JournalTitle>Zeitschrift für Neurologie</JournalTitle><JournalAbbreviatedTitle>Z. Neurol.</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Medicine & Public Health</JournalSubject><JournalSubject Type="Secondary">Neurosciences</JournalSubject><JournalSubject Type="Secondary">Neuroradiology</JournalSubject><JournalSubject Type="Secondary">Neurology</JournalSubject></JournalSubjectGroup></JournalInfo><Volume><VolumeInfo VolumeType="Regular" TocLevels="0"><VolumeIDStart>202</VolumeIDStart><VolumeIDEnd>202</VolumeIDEnd><VolumeIssueCount>4</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular"><IssueInfo TocLevels="0"><IssueIDStart>4</IssueIDStart><IssueIDEnd>4</IssueIDEnd><IssueArticleCount>8</IssueArticleCount><IssueHistory><CoverDate><DateString>25. X. 1972</DateString><Year>1972</Year><Month>12</Month></CoverDate></IssueHistory><IssueCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>1972</CopyrightYear></IssueCopyright></IssueInfo><Article ID="Art1"><ArticleInfo Language="De" ArticleType="OriginalPaper" NumberingStyle="Unnumbered" TocLevels="0" ContainsESM="No"><ArticleID>BF00316175</ArticleID><ArticleDOI>10.1007/BF00316175</ArticleDOI><ArticleSequenceNumber>1</ArticleSequenceNumber><ArticleTitle Language="De">Die moderne medikamentöse Behandlung des Parkinsonismus</ArticleTitle><ArticleTitle Language="En">The modern treatment of parkinsonism</ArticleTitle><ArticleCategory>Surveys Of Progress</ArticleCategory><ArticleFirstPage>257</ArticleFirstPage><ArticleLastPage>280</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2004</Year><Month>8</Month><Day>25</Day></RegistrationDate><Received><Year>1972</Year><Month>7</Month><Day>24</Day></Received></ArticleHistory><ArticleCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>1972</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants><ArticleContext><JournalID>415</JournalID><VolumeIDStart>202</VolumeIDStart><VolumeIDEnd>202</VolumeIDEnd><IssueIDStart>4</IssueIDStart><IssueIDEnd>4</IssueIDEnd></ArticleContext></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>W.</GivenName><FamilyName>Birkmayer</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>E.</GivenName><FamilyName>Neumayer</FamilyName></AuthorName></Author><Affiliation ID="Aff1"><OrgName>L. Boltzmann-Institut für Neurochemie und Neurologische Abteilung der Stadt Wien-Lainz</OrgName><OrgAddress><Country>Österreich</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En"><Heading>Summary</Heading><Para>Evolution, procedure, results and side effects of modern anti-Parkinson treatment are reported. A notable decrease of dopamin, serotonin and norepinephrin in the brainstem of Parkinson patients suggested a substitution of the precursors of these biogenic amines. The administration of <Emphasis Type="SmallCaps">L</Emphasis>-DCPA effected an improvement in the akinesia for a short time only. A combination of <Emphasis Type="SmallCaps">l</Emphasis>-DOPA with a decarboxylase inhibitor (Ro4-4602) produced a more intensive effect over a longer period. Similar results were achieved by high oral dosages, accompanied, however, by marked side effects. The autonomic motor and psychogenic side effects are reported. The DOPA-psychoses are caused by the depletion of serotonin after <Emphasis Type="SmallCaps">l</Emphasis>-DOPA administration. Raised levels of 5-Hydroxyacetic acid were observed in the C.S.F. of psychotic patients. After administration of l-tryptophan the high values of 5 HIAA fell and the patients showed normal behaviour.</Para></Abstract><KeywordGroup Language="En"><Heading>Key words</Heading><Keyword>Parkinson's Disease</Keyword><Keyword><Emphasis Type="SmallCaps">l</Emphasis>-DOPA Treatment of Parkinson's Disease, Side Effects</Keyword><Keyword>Biogenic Amines</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="de"><title>Die moderne medikamentöse Behandlung des Parkinsonismus</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="de"><title>Die moderne medikamentöse Behandlung des Parkinsonismus</title></titleInfo><titleInfo lang="en"><title>The modern treatment of parkinsonism</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The modern treatment of parkinsonism</title></titleInfo><name type="personal"><namePart type="given">W.</namePart><namePart type="family">Birkmayer</namePart><affiliation>L. Boltzmann-Institut für Neurochemie und Neurologische Abteilung der Stadt Wien-Lainz, Österreich</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Neumayer</namePart><affiliation>L. Boltzmann-Institut für Neurochemie und Neurologische Abteilung der Stadt Wien-Lainz, Österreich</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper"></genre><originInfo><publisher>Springer-Verlag</publisher><place><placeTerm type="text">Berlin/Heidelberg</placeTerm></place><dateCreated encoding="w3cdtf">1972-07-24</dateCreated><dateIssued encoding="w3cdtf">1972-12-01</dateIssued><copyrightDate encoding="w3cdtf">1972</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">de</languageTerm><languageTerm type="code" authority="iso639-2b">deu</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Summary: Evolution, procedure, results and side effects of modern anti-Parkinson treatment are reported. A notable decrease of dopamin, serotonin and norepinephrin in the brainstem of Parkinson patients suggested a substitution of the precursors of these biogenic amines. The administration of L-DCPA effected an improvement in the akinesia for a short time only. A combination of l-DOPA with a decarboxylase inhibitor (Ro4-4602) produced a more intensive effect over a longer period. Similar results were achieved by high oral dosages, accompanied, however, by marked side effects. The autonomic motor and psychogenic side effects are reported. The DOPA-psychoses are caused by the depletion of serotonin after l-DOPA administration. Raised levels of 5-Hydroxyacetic acid were observed in the C.S.F. of psychotic patients. After administration of l-tryptophan the high values of 5 HIAA fell and the patients showed normal behaviour.</abstract><note>Surveys Of Progress</note><relatedItem type="host"><titleInfo><title>Zeitschrift für Neurologie</title></titleInfo><titleInfo type="abbreviated"><title>Z. Neurol.</title></titleInfo><genre type="Journal" displayLabel="Archive Journal"></genre><originInfo><dateIssued encoding="w3cdtf">1972-12-01</dateIssued><copyrightDate encoding="w3cdtf">1972</copyrightDate></originInfo><subject><genre>Medicine & Public Health</genre><topic>Neurosciences</topic><topic>Neuroradiology</topic><topic>Neurology</topic></subject><identifier type="ISSN">0012-1037</identifier><identifier type="eISSN">1432-1459</identifier><identifier type="JournalID">415</identifier><identifier type="IssueArticleCount">8</identifier><identifier type="VolumeIssueCount">4</identifier><part><date>1972</date><detail type="volume"><number>202</number><caption>vol.</caption></detail><detail type="issue"><number>4</number><caption>no.</caption></detail><extent unit="pages"><start>257</start><end>280</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1972</recordOrigin></recordInfo></relatedItem><identifier type="istex">37A8F6AFC2350556B8DAF89DB21211B9C932C3FF</identifier><identifier type="DOI">10.1007/BF00316175</identifier><identifier type="ArticleID">Art1</identifier><identifier type="ArticleID">BF00316175</identifier><accessCondition type="use and reproduction" contentType="copyright">Springer-Verlag</accessCondition><recordInfo><recordContentSource>SPRINGER</recordContentSource><recordOrigin>Springer-Verlag, 1972</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000638 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000638 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:37A8F6AFC2350556B8DAF89DB21211B9C932C3FF
|texte= Die moderne medikamentöse Behandlung des Parkinsonismus
}}
| This area was generated with Dilib version V0.6.23. |  |